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Background: On site monitoring of research is one of the most effective ways to ensure compliance during
research conduct. However, it is least carried out primarily for two reasons: presumed high costs both in terms of
human resources and finances; and the lack of a clear framework for undertaking site monitoring. In this paper we
discuss a model for research site monitoring that may be cost effective and feasible in low resource settings.
Methods: This was a retrospective review of research site monitoring reports covering a period of four years.
Results: The monitoring was conducted by the Uganda National Council for Science and Technology, the National
Drug Authority and the National HIV/AIDS Research and Ethics Committee over the period 2007 to 2010.
The monitoring team was usually three members comprising of two experts in research ethics and an assistant. A
total of 28 site monitoring visits covering 40 research projects were reviewed. 25% of the site monitoring reports
revealed violation of the regulatory requirement for valid ethical approval. 36% of the site reports showed some
instances of informed consent violation, 28% showed violation of the rights and welfare of research participants,
38% revealed that sites did not report SAEs to regulatory authorities and many sites lacked adequate GCP and
GCLP. However, most of the sites monitored had adequate facilities to conduct the respective studies and good
working practices.
Conclusion: This model employed by the monitoring teams to evaluate research compliance is effective in
auditing ethical practice. Compliance monitoring is feasible and affordable in a resource limited setting. Research
protocol non compliance is still a major problem in Uganda, and there is need for a pro-active approach to this
vice by all stake holders if ethical conduct of research is to be achieved.
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Review of research by an independent research ethics
committee (REC) is accepted as a global standard for
protecting human research participants [1-9]. Investiga-
tors submit their protocols to a research ethics commit-
tee for their review and approval prior to initiation of a
study. The research ethics committee does initial and
continuing review until completion of the study. Con-
tinuing review is one of the major challenges of research
ethics committees as it involves a number of aspects* Correspondence: ochiengjoe@yahoo.com
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reproduction in any medium, provided the orincluding annual renewals, amendments to the approved
protocols, serious adverse event monitoring, and on site
monitoring. The investigators to a large extent play an
important role because they have to observe a high level
of integrity to comply with ethical standards as well as
report any protocol events accurately. However, research
ethics committees cannot rely solely on reports by inves-
tigators since many times researchers do violate ethical
practice [10-13]. RECs have a responsibility to monitor
activities of approved studies for ethical conduct as well
as adherence to the approved protocol [2].
Research protocol non-compliance occurs in many
parts of the world, probably due to ineffective regula-
tory systems and research participants that are lessl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and ignorance [14-16]. In such settings, protocol non
compliance and violations usually occur for approved
studies because researchers may not be sufficiently edu-
cated about their role in the ethical conduct of research
as well as the need to stick to the regulations [10,17].
Hence need for continuing review through research site
compliance monitoring in order to minimize such un-
ethical tendencies.
In many countries, a good number of research ethics
committees do not monitor approved research protocols
for compliance with the required ethical standards and
scientific principles. Therefore, there is high likelihood
of non-compliance which may compromise the rights
and welfare of research participants.
On site monitoring of research is one of the most ef-
fective ways to ensure compliance during research con-
duct. However, it is least carried out primarily for two
reasons: presumed high costs both in terms of human
resources and finances; and the lack of a clear frame-
work for undertaking site monitoring [18]. In this paper
we discuss a model for research site monitoring that
may be cost effective and feasible in low resource set-
tings. The model is one used in compliance monitoring
by the Uganda National Council for Science and Tech-
nology for approved research projects. The discussion is
based on a comprehensive review of research com-
pliance monitoring reports carried out on projects ap-
proved by the Uganda National Council for Science and
Technology (UNCST).
Objective
The objective of this paper is to demonstrate the feasi-
bility of research compliance monitoring by research
ethics committees and evaluate the effectiveness of the
monitoring tool in a resource limited setting.
Methods
We undertook a retrospective review of research site
monitoring reports covering a period of four years. A
data collection template was developed and utilized in
the evaluation of the compliance monitoring framework
that is employed by the UNCST and Institutional review
Committees.
Although about 50 study projects had been monitored,
the review covered only complete reports which were 28
in number comprising 40 studies and includes study
sites from both the central, east, west and northern
regions of the country. The method used by the com-
pliance monitoring teams included announced or non-
announced visits to the study site. The framework
employed during the monitoring included reviewing the
regulatory documents, informed consent process, stu-
dy related documentation, participants’ welfare, seriousadverse event management and reporting, study related
training and working practices at the site.
The monitoring considered both study document re-
view, observations and verbal interviews with study staff
and participants.
The documents reviewed included; approved study
protocols, REC and UNCST/NDA approvals and their
validity, signed informed consent forms, case report
forms, data collection forms, valid practicing licenses for
clinicians, study related trainings, GCP, GLP and other
research ethics trainings, study related meeting minutes,
SAEs reports, materials transfer agreements, protocol
deviation and protocol violation reports and any other
study documents.
Interview where applicable would be held with investi-
gators and or study staff about their training, knowledge
of the research regulations, study related meetings, any
other studies at the site and how they handled study par-
ticipants. In addition, a chat with research participants
about their knowledge of the study they are participating
in, how they are cared for and facilitation like transport
refund. In some cases, discussions would be held with
the concerned REC.
Observations included assessment of the recruitment
areas and surrounding environment, the laboratories,
the clinics, dispensing areas, storage facilities for drugs
and other study materials, data management areas, num-
ber of study staff and record offices. The assessment of
the facility evaluated the available space in relation to
the approved sample size of the study, number of other
studies at the site, frequency of study visits and the
congestion that was observed during the monitoring
visit. Others included evaluation of the reception for
participants, waiting area, care for research participants,
how research assistants handle participants including
obtaining informed consent, participant waiting time,
how and what amounts were re-imbursed for participant
transportation and if participants at the study site during
lunch were fed.
Ethical review
Permission to review the site monitoring reports was
sought from the Uganda National Council for Science
and Technology. No individual identifying information
or any particular research site was revealed during the
records review.
Results
All the reports were in the custody of the Uganda Na-
tional council for Science and Technology. The monitor-
ing had been conducted by both the Uganda National
Council for Science and Technology, the National Drug
Authority (NDA) as well as the National HIV/AIDS Re-
search and Ethics Committee (NARC), and covered the
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itored included international collaborative studies.
The monitoring team was in most of the cases made
up of three members comprising of two experts in
research ethics and an assistant. The site monitoring re-
ports covered studies that included clinical trials, obser-
vational, behavioral and basic science studies. And the
institutions monitored included; academic institutions,
hospitals, research organizations and research demogra-
phic sites.
All the site monitoring visits were conducted in the
period from 2007 to 2010. Eighteen reports (64.28%) of
the reviewed reports showed that the sites visits had
been conducted by Uganda National Council for Science
and Technology (UNCST), 17.86 of the reviewed reports
showed that the sites visits had been conducted jointly
by the UNCST and the National Drug Authority (NDA),
while another 17.86 of the reviewed reports showed that
the sites visits had been conducted by the National HIV/
AIDS Research Committee (NARC).
Reviewing of the monitoring reports employing the
model used by the monitoring teams
The model used by the monitoring teams looked at
seven elements: regulatory issues, site facilities, informed
consent process and documentation, participant’s wel-
fare, reporting and management of adverse events, study
related training and working practices. These were the
core elements which determined compliance with ap-
proved protocol and approval stipulations. They are de-
tailed in Table 1 and discussed below:
Regulatory documents
Regulatory aspects are issues to do with the adminis-
trative management of the research project to facilitate
ethical conduct and include aspects of documentation of
communications between the research site and regula-
tory agencies like RECs, UNCST and NDA; communica-
tion between research sites and collaborators; as well as
communications between the study coordination team
and the other study staff. Before any conduct of research
in the country, ethical review and approval must be
sought from a competent and independent REC that is
recognized by the UNCST and this is followed by clea-
rance by the UNCST.
In this review, 25% of the site monitoring reports
revealed expired REC and or UNCST approvals which
were not renewed yet studies activities were still ongoing.
The regulation stipulates that research can be conducted
only and whenever there is a valid REC approval.
In addition, 25% of the site reports revealed either
conduct of unapproved research or implementing chan-
ges in the protocol without review and approval by the
concerned RECs, UNCST and or NDA. Any change tothe approved protocol can only be implemented after
approval by an IRC unless it is done to protect the par-
ticipants from eminent harm. Two sites in which were
conducted four studies did not have a regulatory file at
the sites. In such a situation it would be difficult for the
monitoring team to ascertain if the studies had valid ap-
provals as well as other aspects related to administration
of the study.
Other regulatory issues included absence of Materials
Transfer Agreements for exported Human Biological
Materials. In Uganda such materials can only be ethically
exported using a permit from the UNCST and based on
a valid Materials Transfer agreement between the local
and collaborating institutions. Some studies had been
terminated but no evident in form of documentation
existed at the site or any communication to the regula-
tory agencies.
Proper filing of study related documents was lacking
in many instances and even in situations where quick
references would be needed like for SOPs, it was only
the electronic copies of such documents available.
One site had a principal investigator who was a foreign
national that happened to be the team leader of study
activities without being part of the approved protocol
and was not registered with any regulatory agency. In
addition a number of other protocol violations and devi-
ations were not reported to the concerned RECs.
Site facilities
Most of the sites monitored had adequate facilities to
conduct the respective studies. However, a good number
of sites had issues like congestion at recruitment sta-
tions, pharmacies that did not appear organized, limited
training to study staff in study related issues and re-
search ethics, non-restricted data storage facilities, poor
data quality control mechanisms and inadequate/incom-
plete filing of study related records.
Others included lack of quality dispensing and labeling
of drugs as well as lack of SOPs at the respective duty
stations.
Informed consent process and documentation
Informed consent is an essential requirement of ethical
research which demands that a research participants’
rights should be respected. Respect for persons requires
that research participants be given the opportunity to
make choices about what should be done to them. In-
formed consent is not just a form but a process of infor-
mation exchange between the researcher and research
participants on the whole research process. Information
provided should be adequate, clearly understood by
the research participant with decision making capacity
and the research participant should voluntarily decide
to participate.
Table 1 Monitoring activities
Activity Documentation Interview Observation
1. Regulatory documents • Approvals: REC, UNCST and NDA • If approval is valid • Availability of study related
docummnets
• Case report forms • Communication with collaborators
• Data collection forms
• Valid practicing licenses
• Study brochures
2. Site facilities • Recruitment area • How many studies being conducted
at the site
• Availability and the amount of
space compared to the participant
population
• Laboratories • Approval status for all studies • Approval letters
• Clinics, • Number of staff for the study • Available staff
• dispensing areas,
• storage facilities for drugs and
other study materials,





• Signed informed consent forms • How it is obtained • Observe the process of obtaing consent
• Who witnesses
• How long it takes
4. Participant welfare • Amount approved in consent form • How much is given
• Signature by receipient • How amount is determined
• Who gives out the cash
• Ask participant what they get
5. SAEs management
and reporting
• Records of identified SAEs and
their management
• How identified • SAE reports
• Signed SAE reports • How managed
• Status of the SAE
6. Study related training • Training certificates • When trained Training certificates
• Who trained Ability to perform as trained
• Importance of the training
• Knowledge of regulations and study
7. Working practices • Minutes of meetings • Frequency of meetings Meeting minutes
• Communication memos What is discussed in the meetings
• Communication with collaborators How long the meetings take
• Availability of SOPs• Delegation
logs
• Explaining of procedures SOPs at work stations
8. Debriefing Communicate findings of the
monitoring team and get feedback
from research team
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reports showed some instances where either consent
was not obtained, or there was no adequate documen-
tation to prove that informed consent had been ob-
tained. Common consent violations included incomplete
consent forms, for example, some pages missing (5%),using study staff to witness consent for illiterate parti-
cipants (usually study staff have significant conflict of
interest and may not objectively witness consent), (5%);
unsigned consent forms which could imply that an in-
vestigator may have missed reviewing the consent as
required by their own protocol (7.5%); and lack of a
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Ugandan guidelines (20%). Five percent of the studies
had not obtained informed consent from participants,
10% of the studies continued recruiting participants after
expiry of the approved consent form, 7.5% of the studies
had consent forms with only a signature page while an-
other 2.5% of the studies reviewed kept participants in
the study long after expiry of the time indicted in the
consent form. Finally, in a study involving children as-
sent was obtained from children above 13 years only yet
it should be children of age 8 and above as per national
guidelines.
Participants’ welfare
During research conduct, participant’s acceptance to
participate does not in any way remove their rights from
them. Thus protection of participants’ rights and welfare
is an obligation for all of those involved in conduct of
research. Welfare would require that participants’ needs
like meals and refreshments as they wait at the study
site, compensation for time due to forgone opportunities
and transport costs for study related activities are ad-
dressed by the concerned project.
In this review, it was evident that 28% of the reports
showed that participants were either not compensated
for their time or got inadequate compensation. For ex-
ample, in some sites, participants waited for long periods
without a snack or a meal and were not compensation
for time and work lost. In one scenario, participants who
normally would not require hospital admission where
admitted for more than one week in order to participate
in a clinical trial yet no compensation for time lost was
done. However, many of the studies that did not ad-
equately facilitate the participants had been approved
in that form indicating that the ethical review process
had approved the protocol without due consideration
for participant welfare.
SAE: management and reporting
According to the Uganda National Guidelines for con-
ducting research involving humans, all serious adverse
events must be reported to the local IRC as soon as pos-
sible and in any case no later than seven calendar days
of becoming aware of the event. Thereafter, a detailed
report of the SAE should be submitted within eight days.
The requirement to report adverse events to regulatory
authorities does apply to events that are observed among
participants in which a health related intervention is be-
ing administered. In this review, twenty one (21) studies
met the requirement to report SAEs. Eight of the 21 one
studies (38%) did not report SAEs to regulatory author-
ities, two of twenty one (9.5%) reported late while six
out of 21 (28.5%)reported SAEs not reviewed and signed
by the principal investigator.Study related training
It is important that study staff should be knowledgeable
and adequately informed about the study they are exe-
cuting in order to be able to perform efficiently and pro-
vide information to participants whenever need arises.
In this review, many sites lacked adequate GCP and
GCLP. In most cases, only a few members of the study
staff had had training. Some sites did not train their staff
in study related aspects while most of the sites reviewed
had staff who had very little knowledge of research
ethics and ignorance particularly about the Uganda
National Guidelines.
Working practices
In working practices, the site monitors where interested
in aspects that facilitate coordinated execution of the
concerned study including effective communication
throughout the study team, updates on any new findings
about the study, study coordination and how study staff
relate to each other.
Most of the sites reported good working practices like
regular study related meetings some as frequent as daily
updates, weekly or bi-monthly meetings.
However, some sites almost had no work related mee-
tings which would mean study coordination was de-
fective. Worse of were the sites where the principal
investigators were too busy to monitor the conduct of
the study on a regular basis and guide their staff, hence
the name absentee PIs.
Debriefing
At the end of a monitoring visit, the monitoring team
would debrief the investigators on the key issues identi-
fied as well as recommend appropriate action for those
issues that required immediate action as the site awaited
the final report.
Discussion
The model employed by the site monitoring team in
Uganda appears to be quite comprehensive and effective
in identifying many aspects of best research practices as
well as non-compliance at the research sites. The fin-
dings of this review reveal that research protocol non-
compliance is still a problem in the country. To address
this problem, research site monitoring should be inten-
sified, and important aspects should be evaluated in-
cluding; regulatory documents, site facilities, informed
consent process and documentation, participant welfare,
SAE management and reporting, study related training
and working practices at the study site. Research ethics
aspects were found wanting in many situations and this
needs to be improved on.
Concerning regulatory issues, the reviewed reports em-
phasized the fact that non-compliance by investigators is
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toring could be the most appropriate method to minimize
such non-compliance, but is often ignored by the RECs
purportedly due to lack of capacity, requires high cost to
maintain both in terms of human resource as well as
financial resources.
Although Uganda has 14 accredited RECs that review
and approve research currently, only four have reported
carrying out monitoring of approved studies at the site
and only one was found to have records at the UNCST
as evidence for conducting on site compliance monitor-
ing (Table 2). But the current process of accreditation
which is ongoing is expected to set standards and im-
prove on the functionality of many RECs so that effec-
tive execution of their mandates are incorporated in the
day to day business. And when such accreditation is ac-
complished, it will be a positive challenge to such RECs
which have in the past grossly ignored continuing review
including compliance monitoring as an essential compo-
nent of their obligations.
Adequacy of site facilities was relatively good though a
good number had issues of congestion due to limited
space. However, sites should improve skills of study staff
to make them more competent at their work stations.
Investigators should also be in touch with their study
sites and regularly conduct internal auditing.
The informed consent process is an important compo-
nent of ethical research that may not be adequately
understood and or practiced by many investigators. And
this echo’s previous studies [14]. Proactive approaches
like sensitization, continuing education and outreach to
researchers and other stakeholders in research could
yield better outcomes than strict punitive treatment and
humiliation.
Research participants may be reimbursed for lost ear-
nings, travel costs, lunch and other expenses incurred in
taking part in a study; they may also receive free medical
services. Research participants, particularly those who
receive no direct benefit from the research project will
be compensated for inconvenience and time spent. The
compensation or medical services shall not be out of
proportion so as to induce prospective research partici-
pants to consent to participate in the research against
their better judgment [1,4]. Investigators risk comprom-











UNCST 18 64.28% 30 75%
UNCST/NDA 5 17.86% 5 12.5%
NARC 5 17.86% 5 12.5%
Total 28 100% 40 100%think that that such facilitation to participants could re-
sult in undue inducement and or coercion. It is better
for a competent REC to decide on amount of facilitation
acceptable and will not appear to coerce the participants.
Participants should not bear the burden of participating
in research as well as paying for expenses related to their
participation in a study. Investigators and institutional
review boards make payment decisions and that both
healthy and ill subjects in some studies are paid for their
time, for inconvenience, for travel, as incentive, or for
incurring risk. Most organizations require that payment
be prorated and described in the consent document
[19]. It should be noted that in this review, many of the
research participants were not well facilitated due to lack
of due consideration for their compensation and welfare
by the RECs at the time of approval of the study.
None reporting of SAEs and reporting such SAEs
inappropriately are violations of what should be con-
sidered good clinical practice. Ideally, no clinical trials
should be initiated unless all the study staff have un-
dergone training in good clinical practice and where ap-
propriate good laboratory practice in addition to being
equipped with an adequate SAE management and repor-
ting plan. The Investigator undertakes prime responsi-
bility for monitoring and reporting of adverse events to
the regulatory authorities. (1) Both investigators and re-
gulatory agencies should ensure that study staff access
GCP and related training prior to initiation of the study.
SOPs must be present and accessible at each duty sta-
tion and should be adhered to. In this review, the high
rate of non-reporting of such SAEs is a reminder that re-
search ethics and GCP trainings are mandated, should
be appreciated and practiced.
In Uganda based on records available at the UNCST,
about 50 research projects had been monitored over the
period 2007 to 2010 though only three regulatory agen-
cies had actually conducted the visits. Compliance mo-
nitoring should be scaled up and taken up by RECs
because it is feasible even in a low resource setting.
Doing so would be a great break through which would
enhance the protection of the rights and welfare of hu-
man research participants and promote ethical conduct
of research.Conclusion
This model employed by the monitoring teams in
Uganda to evaluate research compliance appears to be
effective in auditing ethical practice and if implemented
appropriately can lead to improved ethical conduct by
researchers as well as improved protection of the rights
and welfare of human research participants.
Compliance monitoring is feasible and affordable in a
resource limited setting as evidenced by this review.
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lem in Uganda, and there is need for a pro-active ap-
proach to this vice by all stake holders including research
regulators, community leaders, political leaders and re-
searchers if ethical conduct of research is to be achieved.
Only competent RECs with compliance monitoring plans
in their activities should be allowed to review and approve
research studies.
Knowledge for both local and international regulations
guiding the conduct of research is still largely ignored by
many researchers with resultant violation of the approved
protocols. As a policy, all study staff should undergo
mandatory training in the relevant guidelines before ever
getting in contact with any study participants.
Limitations of the study
 The relatively small number of reports reviewed.
 Some reports were incomplete hence not included
in the study.
 Lack of adequate detail in some of the reports
because the monitors were different and also the
reasons for monitoring in some cases were different.
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